Histogen Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Susan A. Knudson
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10655 Sorrento Valley Road San Diego CA United States of America 92121
- IPO Date
- Jul 25, 2013
- CIK
- 0001383701
- Website
- histogen.com
- Similar Companies
- Business
- Histogen Inc. (HSTOQ) is a clinical-stage biotechnology company that develops small molecule pan-caspase and caspase selective inhibitors to restore immune function for treating infectious and inflammatory diseases; its lead product candidate, emricasan, targets acute bacterial skin and skin structure infections (ABSSSI) and other infectious diseases through oral administration that reduces inflammation and apoptosis; preclinical candidates include CTS-2090 and CTS-2096, selective caspase-1 inhibitors for various inflammatory conditions. Founded in 2007 and headquartered at 10655 Sorrento Valley Road in San Diego, California, the company previously explored regenerative medicine technologies like hypoxia-generated growth factors for tissue repair before shifting focus to immunotherapy; it operates in the healthcare sector with a lean team of seven employees led by President, CEO, CFO, COO, Chief Compliance Officer, and Corporate Secretary Susan A. Knudson. In April 2024, Histogen filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the Southern District of California to facilitate an orderly wind-down; the plan converted to Chapter 11 liquidation on December 16, 2024, following a September 2023 announcement to discontinue further development and pursue dissolution, with distributions aimed at stakeholders including shareholders.
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
Histogen Announces Second Adjournment of Special Meeting of Stockholders
Histogen Announces Adjournment of Special Meeting of Stockholders
Histogen Announces Board Approval of Complete Liquidation and Dissolution
Top Sectors to Explore for Penny Stocks to Buy
Penny Stock Psychology: Developing a Winning Mindset
Why Is Histogen (HSTO) Stock Up 37% Today?
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know
Buying Biotech Penny Stocks? 3 Things to Look For
Histogen to Present at the H.C. Wainwright Global Investment Conference
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors
Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference